Spotlight on New Oncology Drugs: Access, Costs, and Use

A greater proportion of excellent responses were reported without radioiodine than with radioiodine when treating patients with low-risk thyroid cancer.

Eric Jonasch, MD, believes that the Kidney Cancer Research Consortium may broaden their reach to provide care to many different groups of patients.

Adagrasib elicited higher efficacy in combination with mTOR inhibitors vs alone when treating patients with KRASG12C-mutant non–small cell lung cancer.

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Data from analytical similarity studies and comparative clinical trials support the application of HLX11 in HER2-positive breast cancer.

Options like acupuncture or cannabis use may be viable to help manage symptoms related to gastrointestinal cancer treatment.